FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Pfizer Stops Enrolling Standard Risk Patients in Paxlovid Trial

Pfizer says it will stop enrolling standard risk patients in the EPIC-SR trial of its anti-Covid therapy Paxlovid and submit data to FDA in an NDA.

FDA General

Senate HELP Committee Passes FDA User Fee Bill

The Senate Health, Education, Labor and Pensions Committee passes the FDA Safety and Landmark Advancements (FDASLA) Act, which reauthorizes the agency...

Federal Register

Draft Guide on Quality Risk Management

Federal Register notice: FDA makes available a draft guidance for industry entitled Q9(R1) Quality Risk Management (QRM).

Human Drugs

CDERs Cavazzoni Spearheading Rare Disease Program

CDER director Patrizia Cavazzoni tells FDLI she is personally spearheading the Centers new rare disease efforts to speed and increase the development ...

Biologics

Regenerative Medicine Consensus Standard Guidance

FDA publishes a draft guidance on the voluntary consensus standards recognition program for regenerative medicine therapies.

Biologics

Panel Backs Pfizer, Moderna Covid Vaccines in Young Kids

FDAs Vaccines and Related Biological Products Advisory Committee unanimously votes to recommend the agency expand the Covid-19 emergency use authoriza...

Medical Devices

Quantitative Imaging Assessment in Premarket Submissions

FDA publishes a guidance with recommendations for manufacturers on information to go in premarket submissions for radiological devices with quantitati...

FDA General

Alliance Supports FDA Funding Bill

The Alliance for a Stronger FDA says it supports the FDA funding proposed by a House Agriculture Appropriations subcommittee.

Human Drugs

Make Oral Contraceptives OTC: AMA

The American Medical Association calls on FDA to approve a switch of hormonal oral contraceptives from prescription to over-the-counter status.

Human Drugs

Generic Drug Covid-19 Successes Touted

CDER director Patrizia Cavazzoni praises accomplishments in the generic drug program during Covid-19.